Abstract
AimsWith the specific pharmacological activities including anti-inflammation, anti-oxidant and hypoglycemic effects, Naringin may possess the potential to ameliorate diabetic nephropathy (DN). The purpose of this study was to investigate the anti-DN effect of Naringin and the molecular mechanism by which Naringin ameliorates diabetic renal fibrosis. MethodsThe effects of Naringin on fibronectin (FN) and intercellular adhesion molecule (ICAM-1) as well as the MAPK signaling pathways were detected in streptozotocin (STZ)-induced diabetic mice and high glucose (HG)-cultured glomerular mesangial cells (GMCs) respectively. ResultsNaringin significantly alleviated the renal fibrosis injury and suppressed the expression of FN and ICAM-1, with down-regulating the phosphorylation of ERK1/2 and JNK and inhibiting the activation of the downstream activating protein (AP-1). There were no meaningful difference between Naringin and the MAPK specific inhibitors. ConclusionInhibiting the ERK1/2 and JNK MAPK signaling pathways is probably a novel mechanism by which Naringin alleviates experimental diabetic renal fibrosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
